Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials.
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Rationale Optimization of β-lactam antibiotic dosing for critically ill patients is an intervention that may improve outcomes in severe sepsis. Objectives In this individual patient data meta-analysis of critically ill patients with severe sepsis, we aimed to compare clinical outcomes of those treated with continuous versus intermittent infusion of β-lactam antibiotics. Methods We identified relevant randomized controlled trials comparing continuous versus intermittent infusion of β-lactam antibiotics in critically ill patients with severe sepsis. We assessed the quality of the studies according to four criteria. We combined individual patient data from studies and assessed data integrity for common baseline demographics and study endpoints, including hospital mortality censored at 30 days and clinical cure. We then determined the pooled estimates of effect and investigated factors associated with hospital mortality in multivariable analysis. Measurements and main results We identified three randomized controlled trials in which researchers recruited a total of 632 patients with severe sepsis. The two groups were well balanced in terms of age, sex, and illness severity. The rates of hospital mortality and clinical cure for the continuous versus intermittent infusion groups were 19.6% versus 26.3% (relative risk, 0.74; 95% confidence interval, 0.56-1.00; P = 0.045) and 55.4% versus 46.3% (relative risk, 1.20; 95% confidence interval, 1.03-1.40; P = 0.021), respectively. In a m…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The desirable effects of empiric antiviral therapy are unknown, and as for other antimicrobial agents there is a risk of undesirable effects (165).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [165]
In the citing paper
“Two meta-analyses reported similar results supporting reduced short-term mortality (RR 0.70; 95% CI 0.57–0.87) with prolonged infusion of beta-lactams [232, 233].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [232]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Classification and Regression Trees.
Gordon, A. D., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984) · Biometrics · doi:10.2307/2530946 · Cited by 23,522
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
Cochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,178
Cited by
Items 301–380 of 380
Antiinfektive Therapie: Therapiestrategien bei Sepsis und septischem Schock
Hanses, F. (2020) · Der Internist · doi:10.1007/s00108-020-00855-4 · Cited by 4
Dudoignon, E., Bækgaard, J. S., Léone, M., & Dépret, F. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.04.003 · Cited by 2
Roberts, J. A. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000002862 · Cited by 2
“, all patients receive the same intervention) such as prolonged infusion of beta-lactam antimicrobials have been shown to improve clinical cure in randomized studies and reduce in-hospital mortality in meta-analyses (11).”
BackgroundSelf-citationAre there more differences or similarities between the hospital-acquired pneumonia guidelines?
Kalil, A. C., & Metersky, M. L. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.28 · Cited by 2
“Subsequently, several studies further corroborated the IDSA/ATS PK/PD recommendation (3-5).”
ResultPK / PD and the Drug Delivery Regimen for Infusion in the Critical Care Setting
Sime, F. B., & Roberts, J. A. (2021) · Wiley eBooks · doi:10.1002/9781119772767.ch10 · Cited by 2
Self-citationCombating the Growing Threat of Acinetobacter baumannii Resistance
Goncalves, E. K., Penwell, W. F., & Fiester, S. E. (2025) · Antibiotics · doi:10.3390/antibiotics14070694 · Cited by 2
“In critically ill patients, optimizing PK/PD parameters is vital; for example, transitioning from intermittent to continuous infusion of β -lactams has been associated with improved clinical outcomes [11].”
Abdul-Aziz, M. H., Dulhunty, J. M., Rajbhandari, D., Roberts, J. A., & Lipman, J. (2024) · Internal Medicine Journal · doi:10.1111/imj.16584 · Cited by 1
Self-citationAntimicrobial Resistance and Modern Therapeutics Approaches
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-6077-8 · Cited by 1
Liang, B., Su, J., Wang, Y., Chen, L., Mo, Y., & Xie, B. (2025) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2025.07.016 · Cited by 1
Trozzi, I., Giorgi, B., Paola, R. D., Gatti, M., & Pea, F. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010091 · Cited by 1
“This approach may enhance clinical efficacy while simultaneously reducing the risk of resistance development [7].”
Schatz, L. M., Zöller, M., Scharf, C., & Liebchen, U. (2022) · Die Anaesthesiologie · doi:10.1007/s00101-022-01150-7 · Cited by 1
Kadralinova, A., Bekniyazova, A. Z., Konkayeva, M. E., Yeltayeva, A. A., & Konkayev, A. K. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1148555 · Cited by 1
Mer, M., & Dünser, M. W. (2023) · Springer eBooks · doi:10.1007/978-3-031-47006-6_15 · Cited by 1
Walker, M. K., & Strich, J. R. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-01752-jc · Cited by 1
“Although previous studies have suggested that prolonged infusions of b -lactam antibiotics may reduce mortality, definitive evidence has been lacking (3).”
Zurawska, M., Valadez, A., Harlan, E., Williamson, R., Scheetz, M. H., Neely, M. N., Yarnold, P. R., Kang, M., Donnelly, H. K., Martinez, F., et al. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01760-25 · Cited by 2
Rigo-Bonnin, R. F., & Ramos, P. A. (2016) · Revista del Laboratorio Clínico · doi:10.1016/j.labcli.2016.10.004 · Cited by 2
Pharmacokinetic and Pharmacodynamic Tools to Increase Efficacy
Sinnollareddy, M., Cotta, M. O., & Roberts, J. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-810477-4.00007-6 · Cited by 1
Self-citationTherapie der ambulant erworbenen und nosokomialen Pneumonie
Kramme, E., Dalhoff, K., & Ewig, S. (2019) · Der Klinikarzt · doi:10.1055/a-1024-3284 · Cited by 1
Tschumper, E., Dupuis, K., McCrory, K., & Pitts, W. (2021) · Journal of Pharmacy Technology · doi:10.1177/87551225211034978 · Cited by 2
Chaudhry, D., Lalwani, L. K., & Manjunath, B. G. (2022) · Springer eBooks · doi:10.1007/978-981-16-9929-0_15 · Cited by 1
Dilawri, A., Muir, J., Brodie, D., Abrams, D. C., Agerstrand, C. L., Madahar, P., & Dzierba, A. L. (2024) · Journal of Critical Care · doi:10.1016/j.jcrc.2024.154534 · Cited by 1
Continuous infusion of beta-lactams: a blissful option for the intensive care unit
Shorr, A. F., & Zilberberg, M. D. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.12.47 · Cited by 1
“J Thorac Dis 2016;8(12):E1637-E1640 jtd.”
BackgroundInfluentialAbdul-Aziz, M. H., Hammond, N. E., Brett, S. J., Cotta, M. O., Waele, J. J. D., Tanna, G. L. D., Dulhunty, J. M., Elkady, H., Eriksson, L., Hasan, M. S., et al. (2023) · medRxiv · doi:10.1101/2023.05.15.23289889 · Cited by 1
“Most meta-analyses have included heterogenous patient populations (34-38), including those in whom a difference in effect between prolonged and intermittent infusions is unlikely (e.”
BackgroundSelf-citationAntibiotics, Antivirals, and Antifungals in Critical Care
Shamshirsaz, A. A., & Vaught, A. “. J. (2024) · Wiley eBooks · doi:10.1002/9781119820260.ch19 · Cited by 1
BLISS – Kontinuierliche Infusion von β‑Lactam-Antibiotika bei schwerer Sepsis
Hagel, S., & Pletz, M. W. (2016) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-016-0187-3
“Eine Metaanalyse [2] der bisher veröffentlichten drei RCTs zu Medizinische Klinik - Intensivmedizin und Notfallmedizin 8 · 2016 729 dem Thema konnte zeigen, dass sowohl die Krankenhaussterblichkeit (19,6 vs. 26,3 %, RR 0,74 [95% CI 0,56–1,00], p = 0,045) als auch die Heilungsrate (55,4 vs. 46,3 %, RR 1,20 [95% CI 1,03…”
BackgroundInfluentialAntibiotic Stewardship – Klinische Infektiologie auf der Intensivstation
von Baum, H., & Bracht, H. (2016) · Der Pneumologe · doi:10.1007/s10405-016-0057-y
Kontinuierliche Antibiotikagabe bei schwerer Sepsis vorteilhaft
Budweiser, S. (2016) · Pneumo News · doi:10.1007/s15033-016-0442-6
Abdul-Aziz, M. H. (2016) · The University of Queensland · doi:10.14264/uql.2016.450
Self-citationAntibiotics in critical care: dosing, therapeutic drug monitoring and continuous infusions
Hites, M., & Taccone, F. S. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10004516
Continuous or Extended Intravenous Administration of β-Lactam Antibiotics
Falagas, M. E., & Vardakas, K. Z. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201610-2004le
Appropriate Antimicrobial Therapy in Critically Ill Patients
Sime, F. B., & Roberts, J. A. (2017) · Hot topics in acute care surgery and trauma · doi:10.1007/978-3-319-59704-1_21
Self-citationProlonged Infusion of Beta-lactam Antibiotics in Critically Ill Patients: Revisiting the Evidence
Dhaese, S. A. M., Stove, V. V., & Waele, J. J. D. (2018) · Annual update in intensive care and emergency medicine · doi:10.1007/978-3-319-73670-9_5
Medikamentengabe und allgemeine Komplikationen bei extrakorporalen Verfahren
Brinkmann, A., Bürle, M., Frey, O. R., König, C., Richter, D., Röhr, A. C., & Träger, K. (2019) · Elsevier eBooks · doi:10.1016/b978-3-437-22791-2.00002-8
Barton, G. (2019) · Liverpool John Moores University · doi:10.24377/ljmu.t.00011543
“A 2016 review (Roberts et al., 2016) had very specific inclusion criteria”
BackgroundResultInfluentialShashikala., N., Manasa, S., & Venkatesh Vikram, H. C. (2020) · Tropical Journal of Pathology and Microbiology · doi:10.17511/jopm.2020.i04.08
Should prolonged ceftriaxone infusions be preferred in septic patients?
Kara, E., Bahap, M., & İnkaya, A. Ç. (2020) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.06.077
Sumi, C. D. (2020) · The University of Queensland · doi:10.14264/uql.2020.871
Antiinfektive Therapie: Therapiestrategien bei Sepsis und septischem Schock
Hanses, F. (2020) · Wiener klinisches Magazin · doi:10.1007/s00740-020-00373-x
Suraj, K. P., & Chandran, A. (2021) · Journal of Advanced Lung Health · doi:10.4103/jalh.jalh_11_20
Antibiotic Therapy for Respiratory Infection
Jones, I. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00246-8
Empiric Antimicrobial Therapy in Critically Ill Septic Patients
Trifi, A., Abdellatif, S., Trabelsi, S., & Lakhal, S. B. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98327
Kanno, K., Fujiwara, N., Sashinami, A., & Narita, M. (2021) · Journal of the Japanese Society of Intensive Care Medicine · doi:10.3918/jsicm.28_224
Opportunistic Bacterial, Fungal and Viral Infections in Lung Transplantation
Chan, G. C., Lynch, B., Murray, M., & Hannan, M. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00259-6
Böll, B., Kochanek, M., & Shimabukuro‐Vornhagen, A. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-15335-8.00012-2
Antiinfektive Therapie: Therapiestrategien bei Sepsis und septischem Schock
Hanses, F. (2021) · Wiener klinisches Magazin · doi:10.1007/s00740-021-00387-z
“Kritisch kranke Patienten profitieren am ehesten von einer verlängerten Infusionsdauer (oder sogar Dauerinfusion [26]) von β-Laktamen.”
BackgroundCalandra, T., & Guery, B. P. (2018) · Springer eBooks · doi:10.1007/978-3-319-73506-1_12
Comment bien choisir l’antibiothérapie antipyocyanique ?
Roger, C. (2022) · Le Praticien en Anesthésie Réanimation · doi:10.1016/j.pratan.2022.10.004
New Diagnostic and Therapeutic Perspectives
Ruiz‐Rodríguez, J. C., Chiscano‐Camón, L., Menchaca, E.-P. P., & Ferrer, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88271-2.00015-8
Antibiotika, Antibiotikaprophylaxe und Antimykotika in der Intensivmedizin
Wetzstein, N., Vehreschild, J. J., & Vehreschild, M. J. G. T. (2023) · Springer Reference Medizin · doi:10.1007/978-3-642-54675-4_82-2
Antibiotika, Antibiotikaprophylaxe und Antimykotika in der Intensivmedizin
Wetzstein, N., Vehreschild, J. J., & Vehreschild, M. J. G. T. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-68699-7_82
Walker, M. K., & Strich, J. R. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-01751-jc
Continuous vs Intermittent β-Lactam Antibiotic Infusions for Sepsis
Han, J., Lin, Q., & Shan, D. (2024) · JAMA · doi:10.1001/jama.2024.23272
Karvunidis, T., & Kralovcova, M. (2024) · Anesteziologie a intenzivní medicína · doi:10.36290/aim.2024.049
Chiriac, U., & Morath, B. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21194-2.00029-1
Mohr, A., Gottschling, M., & Sicker, N. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21194-2.00003-5
Liu, R., Yao, L., Gao, Y., Bao, J., & Li, L. (2025) · Global Insights in Medicine and Nursing · doi:10.65140/gimn202501.4
New PK/PD profile improvement following cephalosporin extended infusion : a systematic review
Nurani, M. R., Widyati, W., & Yasin, N. M. (2024) · JURNAL ILMU KEFARMASIAN INDONESIA · doi:10.35814/jifi.v22i2.1583
“Early detection and administration of antibiotic therapy is the main standard for treating cases of infection [2] .”
Li, X., Long, Y., Wu, G., Li, R., Zhou, M., He, A., & Jiang, Z. (2023) · Figshare · doi:10.6084/m9.figshare.24751220
Zhao, Y., Zang, B., & Wang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.25242414
Li, X., Long, Y., Wu, G., Li, R., Zhou, M., He, A., & Jiang, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26649783
Zhao, Y., Zang, B., & Wang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26682439
Laporte-Amargós, J., Gudiol, C., Arnan, M., Puerta‐Alcalde, P., Carmona-Torre, F., Huguet, M., Albasanz‐Puig, A., Parody, R., Garcia-Vidal, C., del Pozo, J. L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12324617
Meenks, S. D., Punt, N. C., le Noble, J. L. M. L., Foudraine, N. A., Neef, K., & Janssen, P. K. C. (2024) · Figshare · doi:10.6084/m9.figshare.26572669
Meenks, S. D., Punt, N. C., le Noble, J. L. M. L., Foudraine, N. A., Neef, K., & Janssen, P. K. C. (2024) · Figshare · doi:10.6084/m9.figshare.26572666
Zhao, Y., Zang, B., & Wang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26682436
Sieswerda, E., Bax, H. I., Hoogerwerf, J. J., de Boer, M. G. J., Boermeester, M. A., Bonten, M. J. M., Dekker, D., van Wijk, R. G., Juffermans, N. P., Kuindersma, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479548
Zhao, Y., Zang, B., & Wang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.25242233
Li, X., Long, Y., Wu, G., Li, R., Zhou, M., He, A., & Jiang, Z. (2024) · Figshare · doi:10.6084/m9.figshare.24751628
Buensalido, J. A. L., Malundo, A. F. G., Aherrera, J. A. M., Magno, J. D. A., Maramara, M. K. P., Punzalan, F. E. R., Tolosa, M. T. S., Briones, G., Hernandez, A. M. R., Pantaleon, A. F., et al. (2022) · Philippine Journal of Internal Medicine · doi:10.65564/pjim.10a45be121
Mahmoud, R. S., Ahmed, M. M., Hassan, S. B., & Abdel-Latif, M. (2026) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-026-00935-6
Shoja, S., Cheshmberah, M., Shamseddin, J., Hajizadeh, F., & Farahani, A. S. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11581-9
“…imper - ative to interpret these findings with caution, as therapeutic success may depend on optimized dosing strategies, the site of infection, and pharmacokinetic/pharmacodynamic considerations, rather than relying on piperacillin-tazobactam as a consistently reliable treatment option [13, 24].”
Lee, S., Park, S., Shin, M. G., Jo, H. G., Jeong, K., Yoon, J.-E., Ye, K. N., Choi, Y. J., Choe, M., Yang, S., et al. (2026) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-026-01740-9
“2) to adjust antibiotic doses based on altered pharmacokinetics in critically ill patients due to physiologic changes associated with critical illness [49–51].”
Ying, H. (2026) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2025.10.031
Varghese, A. R., Umer, S., & Vijayan, M. (2026) · Medical Hypotheses · doi:10.1016/j.mehy.2026.112014
Alghanem, S. S., Al-Ajmi, W., & Awad, A. I. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2692481
Xie, Y., Zhao, J., Li, N., Zhang, M., Yang, Z., Feng, Q., Fang, H., Chen, Y., Li, W., & Wang, R. (2026) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2026.06.008
Ников, Х., Chernopolsky, P., Bozhkov, V., & Madzhov, R. (2023) · Surgery · doi:10.67572/hn8gxb83
Arsène, A., Oualha, M., Rambaud, J., Benaboud, S., Urien, S., Grimaud, M., Renolleau, S., Léger, P., Hirt, D., Tréluyer, J., et al. (2026) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000004016
Geneva, I. I., Medugbon, K., Thomas, S. J., & Call, A. (2026) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2026.10911
“…studies have consistently demonstrated that maximizing the time free drug concentrations remain above the minimum inhibitory concentration improves bacterial killing and may reduce the emergence of resistance 24,25 withthe associatedclinicaloutcomes being recently reviewed by our group.”
Metadata
- Authors
- Roberts, J. A., Abdul-Aziz, M.-H., Davis, J. S., Dulhunty, J. M., Cotta, M. O., Myburgh, J., Bellomo, R., & Lipman, J.
- Affiliations
- The University of Queensland (AU)
- International Islamic University Malaysia (MY)
- John Hunter Hospital (AU)
- Redcliffe Hospital (AU)
- The George Institute for Global Health (GB)
- Austin Hospital (AU)
- Department of Intensive Care Medicine and
- Corresponding author
- Roberts, Jason A.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-09
- Volume
- 194
- Issue
- 6
- Pages
- 681-691
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2298261704
- Cited by
- 379
- References
- 46
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 45 · 2023: 51 · 2022: 37 · 2021: 44 · 2020: 43 · 2019: 38 · 2018: 38 · 2017: 39 · 2016: 15
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Health and Medical Research Council of Australia (APP1048652)
- Australian National Health and Medical Research Council (APP1099452)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Keywords
- severe sepsis, beta-lactam antibiotics, continuous infusion, intermittent infusion, antibiotic dosing, in-hospital mortality, clinical cure, critically ill patients, APACHE II score, renal replacement therapy, non-fermenting Gram-negative bacilli
- MeSH terms
- Aged, Anti-Bacterial Agents, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Proportional Hazards Models, Randomized Controlled Trials as Topic, Sepsis, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.